Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Galvão, S. Justi (2015)
An overview on the ecology of Triatominae (Hemiptera:Reduviidae).Acta tropica, 151
Stephen Patterson, S. Wyllie (2014)
Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospectsTrends in Parasitology, 30
P. Loiseau, S. Cojean, J. Schrével (2011)
Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistanceParasite : journal de la Société Française de Parasitologie, 18
A. Kuemmerle, C. Schmid, V. Kande, W. Mutombo, M. Ilunga, Ismael Lumpungu, Sylvain Mutanda, Pathou Nganzobo, Digas Ngolo, Mays Kisala, O. Mordt (2020)
Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the CongoPLoS Neglected Tropical Diseases, 14
O. Touré, S. Rulisa, A. Anvikar, B. Rao, Pitabas Mishra, R. Jalali, S. Arora, A. Roy, N. Saha, S. Iyer, Pradeep Sharma, N. Valecha (2015)
Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label studyMalaria Journal, 14
B. Lell, R. Ruangweerayut, J. Wiesner, M. Missinou, A. Schindler, T. Baranek, M. Hintz, D. Hutchinson, H. Jomaa, P. Kremsner (2003)
Fosmidomycin, a Novel Chemotherapeutic Agent for MalariaAntimicrobial Agents and Chemotherapy, 47
L. Cui, X. Su (2009)
Discovery, mechanisms of action and combination therapy of artemisininExpert Review of Anti-infective Therapy, 7
Roger C. Finch, D. Greenwood, S. Norrby, R. Whitley, J. Lentino (2003)
Antibiotic and chemotherapy : anti-infective agents and their use in therapy
V. Mesu, Wilfried Kalonji, Clélia Bardonneau, Olaf Mordt, S. Blesson, F. Simon, Sophie Delhomme, Sonja Bernhard, Willy Kuziena, J. Lubaki, Steven Vuvu, Pathou Ngima, Hélène Mbembo, M. Ilunga, Augustin Bonama, Josué Heradi, Jean Solomo, Guylain Mandula, Lewis Badibabi, Francis Dama, Papy Lukula, D. Tete, C. Lumbala, B. Scherrer, Nathalie Strub-Wourgaft, A. Tarral (2018)
Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trialThe Lancet, 391
E. Khalil, Teklu Weldegebreal, B. Younis, R. Omollo, A. Musa, Workagegnehu Hailu, A. Abuzaid, T. Dorlo, Zewdu Hurissa, Sisay Yifru, William Haleke, Peter Smith, S. Ellis, M. Balasegaram, A. El-Hassan, G. Schoone, M. Wasunna, Robert Kimutai, T. Edwards, A. Hailu (2014)
Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised TrialPLoS Neglected Tropical Diseases, 8
T. Umeda, N. Tanaka, Y. Kusakabe, M. Nakanishi, Y. Kitade, Kazuo Nakamura (2011)
Molecular basis of fosmidomycin's action on the human malaria parasite Plasmodium falciparumScientific Reports, 1
N. Valecha, D. Savargaonkar, Bina Srivastava, B. Rao, S. Tripathi, N. Gogtay, Sanjay Kochar, Nalli Babu, Vijaya Kumar, Girish Rajadhyaksha, J. Lakhani, Bhagirath Solanki, R. Jalali, S. Arora, A. Roy, N. Saha, S. Iyer, Pradeep Sharma, A. Anvikar (2016)
Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label studyMalaria Journal, 15
M. Makanga, S. Krudsood (2009)
The clinical efficacy of artemether/lumefantrine (Coartem®)Malaria Journal, 8
A. Leitgeb, P. Charunwatthana, Ronnatrai Rueangveerayut, Chirapong Uthaisin, K. Silamut, K. Chotivanich, Patima Sila, K. Moll, Sue Lee, M. Lindgren, E. Holmer, A. Färnert, M. Kiwuwa, J. Kristensen, C. Herder, J. Tarning, M. Wahlgren, A. Dondorp (2017)
Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malariaPLoS ONE, 12
(2020)
Medicines for Malaria Venture, A proof-of-concept study to assess the effect of MMV390048 against early Plasmodium falciparum blood stage infection in healthy participants
L. Diniz, I. Caldas, P. Guedes, G. Crepalde, M. Lana, C. Carneiro, A. Talvani, J. Urbina, M. Bahia (2010)
Effects of Ravuconazole Treatment on Parasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruziAntimicrobial Agents and Chemotherapy, 54
Somporn Saiwaew, Juntima Sritabal, N. Piaraksa, Srisuda Keayarsa, R. Ruengweerayut, Chirapong Utaisin, Patima Sila, R. Niramis, R. Udomsangpetch, P. Charunwatthana, E. Pongponratn, S. Pukrittayakamee, A. Leitgeb, M. Wahlgren, Sue Lee, N. Day, N. White, A. Dondorp, K. Chotivanich (2017)
Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytesPLoS ONE, 12
C. Morillo, J. Marin-Neto, Á. Avezum, S. Sosa-Estani, A. Rassi, F. Rosas, Erick Villena, R. Quiroz, Rina Bonilla, C. Britto, F. Guhl, E. Velázquez, L. Bonilla, Brandi Meeks, P. Rao-Melacini, J. Pogue, A. Mattos, J. Lazdins, A. Rassi, S. Connolly, S. Yusuf (2015)
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.The New England journal of medicine, 373 14
G. Schmuñis, Z. Yadón (2010)
Chagas disease: a Latin American health problem becoming a world health problem.Acta tropica, 115 1-2
W. Foye, T. Lemke, David Williams (2002)
Foye's Principles of Medicinal Chemistry
M. Jiménez-Díaz, D. Ebert, Yandira Salinas, Anupam Pradhan, Adele Lehane, Marie-Eve Myrand-Lapierre, Kathleen O’Loughlin, David Shackleford, Mariana Almeida, A. Carrillo, Julie Clark, Adelaide Dennis, Jonathon Diep, Xiaoyan Deng, Sandra Duffy, A. Endsley, Greg Fedewa, W. Guiguemde, María Gómez, Gloria Holbrook, J. Horst, Charles Kim, Jian Liu, Marcus Lee, A. Matheny, M. Martínez, Gregory Miller, A. Rodríguez-Alejandre, Laura Sanz, M. Sigal, Natalie Spillman, P. Stein, Z. Wang, Fangyi Zhu, D. Waterson, S. Knapp, A. Shelat, V. Avery, D. Fidock, F. Gamo, S. Charman, J. Mirsalis, Hongshen Ma, S. Ferrer, K. Kirk, Iñigo Angulo-Barturen, D. Kyle, J. Derisi, D. Floyd, R. Guy (2014)
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of PlasmodiumProceedings of the National Academy of Sciences, 111
Chunge Cn, J. Owate, H. Pamba, L. Donno (1990)
Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.Transactions of the Royal Society of Tropical Medicine and Hygiene, 84 2
E. Klein (2013)
Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread.International journal of antimicrobial agents, 41 4
L. Miller, X. Su (2011)
Artemisinin: Discovery from the Chinese Herbal GardenCell, 146
(2021)
Developing antimalarials to save lives
(2003)
Nifurtimox-eflornithine combination therapy (NECT)
Ayenew Addisu, W. Adriaensen, Arega Balew, M. Asfaw, E. Diro, Amadou Djirmay, Desalegn Gebree, Getahun Seid, Hailemariam Begashaw, A. Harries, Abera Adugna, Zeleke Jejaw, E. Kamau, Tigist Kelbo, M. Manzi, Dana Daniel, Ashok Moloo, P. Olliaro, P. Owiti, J. Reeder, Mbazi Senkoro, K. Takarinda, R. Terry, C. Timire, Samson Tucho, H. Tweya, Yeshanehe Wendemagegn, K. Verdonck, F. Vogt, Saskia Henten, J. Griensven, Bekele Worku, M. Zolfo, R. Zachariah (2019)
Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front lineBMJ Global Health, 4
K. Ritmeijer, R. Horst, Solomon Chane, Endashaw Aderie, T. Piening, S. Collin, R. Davidson (2011)
Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 53 12
C. Miranda-Verástegui, Gianfranco Tulliano, T. Gyorkos, Wessmark Calderón, E. Rahme, B. Ward, M. Cruz, A. Llanos-Cuentas, G. Matlashewski (2009)
First-Line Therapy for Human Cutaneous Leishmaniasis in Peru Using the TLR7 Agonist Imiquimod in Combination with Pentavalent AntimonyPLoS Neglected Tropical Diseases, 3
A. Anderson (2003)
The process of structure-based drug design.Chemistry & biology, 10 9
C. Morillo, H. Waskin, S. Sosa-Estani, Maria Bangher, C. Cuneo, Rodolfo Milesi, Marcelo Mallagray, W. Apt, J. Beloscar, J. Gascón, I. Molina, L. Echeverría, H. Colombo, J. Pérez-Molina, F. Wyss, Brandi Meeks, L. Bonilla, P. Gao, Bomin Wei, Michael McCarthy, S. Yusuf (2017)
Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.Journal of the American College of Cardiology, 69 8
N. White, T. Dương, Chirapong Uthaisin, F. Nosten, A. Phyo, B. Hanboonkunupakarn, S. Pukrittayakamee, P. Jittamala, Kittiphum Chuthasmit, Ming-Sin Cheung, Yiyan Feng, Ruobing Li, Baldur Magnusson, M. Sultan, D. Wieser, X. Xun, R. Zhao, T. Diagana, P. Pertel, F. Leong (2016)
Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria.The New England journal of medicine, 375 12
Carlos Chaccour, Kevin Kobylinski, Q. Bassat, T. Bousema, C. Drakeley, P. Alonso, B. Foy (2013)
Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for eliminationMalaria Journal, 12
(2015)
A randomized, double-blind, placebocontrolled trial of rosiglitazone as adjunctive therapy for P. falciparum infection
Jing Yang, Yingke He, Yinbao Li, Xing Zhang, Y. Wong, Shengnan Shen, Tianyu Zhong, Jianbin Zhang, Qian Liu, Jigang Wang (2020)
Advances in the research on the targets of anti-malaria actions of artemisininPharmacology & Therapeutics, 216
V. Pathak, R. Colah, K. Ghosh (2015)
Tyrosine kinase inhibitors: New class of antimalarials on the horizon?Blood cells, molecules & diseases, 55 2
A. Musa, B. Younis, A. Fadlalla, C. Royce, M. Balasegaram, M. Wasunna, A. Hailu, T. Edwards, R. Omollo, M. Mudawi, G. Kokwaro, A. El-Hassan, E. Khalil (2010)
Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding StudyPLoS Neglected Tropical Diseases, 4
Daniel Donovan, P. Aillard, M. Berger, Aurélien Torre, D. Petkova, Christian Knittl‐Frank, D. Geerdink, M. Kaiser, N. Maulide (2018)
C−H Activation Enables a Concise Total Synthesis of Quinine and Analogues with Enhanced Antimalarial ActivityAngewandte Chemie (International Ed. in English), 57
Seth Thacker, Ian McWilliams, Béatrice Bonnet, Lydia Halie, S. Beaucage, Swaksha Rachuri, R. Dey, R. Duncan, F. Modabber, Stephen Robinson, G. Bilbe, B. Arana, D. Verthelyi (2020)
CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasisPLoS Neglected Tropical Diseases, 14
C. Lanteri, R. Tidwell, S. Meshnick (2007)
The Mitochondrion Is a Site of Trypanocidal Action of the Aromatic Diamidine DB75 in Bloodstream Forms of Trypanosoma bruceiAntimicrobial Agents and Chemotherapy, 52
F. Mzayek, Haiyan Deng, Frances Mather, Elizabeth Wasilevich, Huayin Liu, C. Hadi, D. Chansolme, Holly Murphy, B. Melek, A. Tenaglia, D. Mushatt, A. Dreisbach, J. Lertora, D. Krogstad (2007)
Randomized Dose-Ranging Controlled Trial of AQ-13, a Candidate Antimalarial, and Chloroquine in Healthy VolunteersPLoS Clinical Trials, 2
G. Simon (2016)
Impacts of neglected tropical disease on incidence and progression of HIV/AIDS, tuberculosis, and malaria: scientific links.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 42
A. Rassi, J. Marin-Neto (2010)
Chagas diseaseThe Lancet, 375
Rosauro Varo, V. Crowley, António Sitoe, L. Madrid, L. Serghides, Rubão Bila, Hélio Mucavele, A. Mayor, Q. Bassat, K. Kain (2017)
Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malariaMalaria Journal, 16
Robin Howe, Robert Spencer (1996)
Cotrimoxazole. Rationale for re-examining its indications for use.Drug safety, 14 4
Emily Dickie, Federica Giordani, M. Gould, P. Mäser, C. Burri, J. Mottram, Srinivasa Rao, M. Barrett (2020)
New Drugs for Human African Trypanosomiasis: A Twenty First Century Success StoryTropical Medicine and Infectious Disease, 5
D. Paterson (2017)
Cefadroxil, cephaloridine, cephacetrile, cephapirin, cephradine, and other rarely used first-generation cephalosporins
S. Kapishnikov, E. Hempelmann, M. Elbaum, J. Als-Nielsen, L. Leiserowitz (2021)
Malaria Pigment Crystals: The Achilles′ Heel of the Malaria ParasiteChemmedchem, 16
S. Lahiry, eep, S. Rajasree (2017)
Antimalaria Drug Development & Pipeline, 5
Mínistério Saúde (2010)
Guia prático de tratamento da malária no Brasil
I. Ben-Zvi, S. Kivity, P. Langevitz, Y. Shoenfeld (2011)
Hydroxychloroquine: From Malaria to AutoimmunityClinical Reviews in Allergy & Immunology, 42
P. Rosenthal (2016)
Azithromycin for Malaria?The American Journal of Tropical Medicine and Hygiene, 95
A. Lin, M. Lee, D. Klayman (1989)
Antimalarial activity of new water-soluble dihydroartemisinin derivatives. 2. Stereospecificity of the ether side chain.Journal of medicinal chemistry, 32 6
Better health moves humanity forward
J. Seeberger, S. Daoud, J. Pammer (2003)
Transient effect of topical treatment of cutaneous leishmaniasis with imiquimodInternational Journal of Dermatology, 42
(2021)
Medicines for Malaria Venture, First-ever drug compound developed on African soil, an antimalarial, to move to human trials
A. Sokolova, S. Wyllie, Stephen Patterson, Sandra Oza, K. Read, A. Fairlamb (2010)
Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African TrypanosomiasisAntimicrobial Agents and Chemotherapy, 54
(2021)
Fourth-generation immucillin derivative DI4G associated therapy in cutaneous leishmaniasis
Wilian Cortopassi, Aline Oliveira, A. Guimarães, M. Rennó, A. Krettli, T. França (2011)
Docking Studies on the Binding of Quinoline Derivatives and Hematin to Plasmodium Falciparum Lactate DehydrogenaseJournal of Biomolecular Structure and Dynamics, 29
N. Mbeye, F. Kuile, M. Davies, K. Phiri, M. Egger, G. Wandeler (2014)
Cotrimoxazole prophylactic treatment prevents malaria in children in sub‐Saharan Africa: systematic review and meta‐analysisTropical Medicine & International Health, 19
A. Fairlamb, G. Henderson, A. Cerami (1989)
Trypanothione is the primary target for arsenical drugs against African trypanosomes.Proceedings of the National Academy of Sciences of the United States of America, 86 8
James Thomas, N. Baker, Sebastian Hutchinson, Caia Dominicus, Anna Trenaman, Lucy Glover, S. Alsford, D. Horn (2018)
Insights into antitrypanosomal drug mode-of-action from cytology-based profilingPLoS Neglected Tropical Diseases, 12
W. Wilson, F. Tanious, Amanda Mathis, D. Tevis, James Hall, D. Boykin (2008)
Antiparasitic compounds that target DNA.Biochimie, 90 7
A. Hasslocher-Moreno, P. Brasil, A. Sousa, S. Xavier, M. Chambela, G. Silva (2012)
Safety of benznidazole use in the treatment of chronic Chagas' disease.The Journal of antimicrobial chemotherapy, 67 5
S. Wyllie, Michael Thomas, Stephen Patterson, Sabrinia Crouch, M. Rycker, R. Lowe, S. Gresham, Michael Urbaniak, T. Otto, L. Stojanovski, Frederick Simeons, Sujatha Manthri, Lorna MacLean, F. Zuccotto, Nadine Homeyer, H. Pflaumer, Markus Boesche, Lalitha Sastry, P. Connolly, S. Albrecht, M. Berriman, G. Drewes, David Gray, S. Ghidelli-Disse, S. Dixon, J. Fiandor, P. Wyatt, M. Ferguson, A. Fairlamb, T. Miles, K. Read, I. Gilbert (2018)
Cyclin-dependent kinase 12, a novel drug target for visceral leishmaniasisNature, 560
A. Ugarte, S. Porta, R. Ríos, A. Martínez-zapico, N. Ortego-Centeno, N. Agesta, G. Ruiz‐Irastorza (2018)
Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activityLupus, 27
S. Meshnick (2002)
Artemisinin: mechanisms of action, resistance and toxicity.International journal for parasitology, 32 13
I. Sagara, A. Oduro, M. Mulenga, Y. Dieng, B. Ogutu, A. Tiono, P. Mugyenyi, A. Sié, M. Wasunna, K. Kain, A. Djimde, Shirsendu Sarkar, R. Chandra, J. Robbins, M. Dunne (2014)
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adultsMalaria Journal, 13
J. Molina, O. Martins-Filho, Z. Brener, A. Romanha, D. Loebenberg, J. Urbina (2000)
Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan ParasiteTrypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine HostsAntimicrobial Agents and Chemotherapy, 44
Michael Cappera, O. PaulM., Neillb, Nicholas Fisherc, R. Strangea, Darren Mossc, Stephen Wardc, Neil Berryb, Alexandre Lawrensonb, S. Hasnaina, Giancarlo Biaginic, S. Antonyuka (2015)
Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1Proceedings of the National Academy of Sciences, 112
F. Chappuis, Nitya Udayraj, K. Stietenroth, Ann Meussen, P. Bovier (2005)
Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 41 5
M. Zajac, I. Muszalska, A. Sobczak, Adrianna Dadej, Szymon Tomczak, A. Jelińska (2019)
Hepatitis C - New drugs and treatment prospects.European journal of medicinal chemistry, 165
V. Georgiev, K. Western, J. McGOWAN (2008)
National Institute of Allergy and Infectious Diseases, NI
B. Lell, P. Kremsner (2002)
Clindamycin as an Antimalarial Drug: Review of Clinical TrialsAntimicrobial Agents and Chemotherapy, 46
Amélie Bihan, R. Kanter, Iñigo Angulo-Barturen, C. Binkert, C. Boss, R. Brun, R. Brunner, Stephan Buchmann, J. Burrows, K. Dechering, M. Delves, S. Ewerling, S. Ferrer, Christoph Fischli, Francisco Gamo-Benito, Nina Gnädig, Bibia Heidmann, M. Jiménez-Díaz, D. Leroy, M. Martínez, Solange Meyer, Joerg Moehrle, Caroline Ng, Rintis Noviyanti, A. Ruecker, L. Sanz, R. Sauerwein, C. Scheurer, Sarah Schleiferboeck, R. Sinden, Christopher Snyder, J. Straimer, Grennady Wirjanata, J. Marfurt, R. Price, T. Weller, W. Fischli, D. Fidock, M. Clozel, S. Wittlin (2016)
Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy ModelingPLoS Medicine, 13
A. Thompson, Patrick O’Connor, A. Marshall, V. Yardley, L. Maes, Suman Gupta, D. Launay, S. Braillard, E. Chatelain, S. Franzblau, Baojie Wan, Yuehong Wang, Zhenkun Ma, Christopher Cooper, W. Denny (2017)
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral LeishmaniasisJournal of Medicinal Chemistry, 60
K. Goa, D. Campoli-Richards (1987)
Pentamidine IsethionateDrugs, 33
Jana Held, Christian Supan, C. Salazar, H. Tinto, L. Bonkian, A. Nahum, A. Sié, S. Abdulla, C. Cantalloube, Elhadj Djeriou, M. Bouyou-Akotet, B. Ogutu, B. Mordmüller, A. Kreidenweiss, M. Siribie, S. Sirima, P. Kremsner (2017)
Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patientsMalaria Journal, 16
M. Phillips, J. Lotharius, K. Marsh, John White, A. Dayan, K. White, Jacqueline Njoroge, Farah Mazouni, Y. Lao, Sreekanth Kokkonda, D. Tomchick, Xiao-Yi Deng, T. Laird, S. Bhatia, Sandra March, Caroline Ng, D. Fidock, S. Wittlin, S. Wittlin, M. Lafuente-Monasterio, Francisco Benito, Laura Alonso, M. Martínez, M. Jiménez-Díaz, S. Bazaga, Iñigo Angulo-Barturen, J. Haselden, J. Louttit, Yi Cui, A. Sridhar, A. Zeeman, C. Kocken, R. Sauerwein, K. Dechering, V. Avery, Sandra Duffy, M. Delves, R. Sinden, A. Ruecker, Kristina Wickham, R. Rochford, Janet Gahagen, L. Iyer, E. Riccio, J. Mirsalis, Ian Bathhurst, T. Rueckle, Xavier Ding, B. Campo, D. Leroy, M. Rogers, P. Rathod, J. Burrows, S. Charman (2015)
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaScience Translational Medicine, 7
M. Kaiser, M. Bray, Monica Cal, Bernadette Trunz, E. Torreele, R. Brun (2011)
Antitrypanosomal Activity of Fexinidazole, a New Oral Nitroimidazole Drug Candidate for Treatment of Sleeping SicknessAntimicrobial Agents and Chemotherapy, 55
Jonathan Alpern, R. López-Vélez, W. Stauffer (2017)
Access to benznidazole for Chagas disease in the United States—Cautious optimism?PLoS Neglected Tropical Diseases, 11
M. Chughlay, Emilie Rossignol, C. Donini, Myriam Gaaloul, U. Lorch, Simon Coates, G. Langdon, T. Hammond, J. Möhrle, S. Chalon (2020)
First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotectionBritish Journal of Clinical Pharmacology, 86
A. Kardashian, P. Pockros (2017)
Novel emerging treatments for hepatitis C infection: a fast-moving pipelineTherapeutic Advances in Gastroenterology, 10
S. Mohanty, S. Mishra, S. Satpathy, S. Dash, J. Patnaik (1997)
alpha, beta-Arteether for the treatment of complicated falciparum malaria.Transactions of the Royal Society of Tropical Medicine and Hygiene, 91 3
Cedric Graebin, F. Uchôa, Lilian Bernardes, V. Campo, I. Carvalho, V. Eifler-Lima (2009)
Antiprotozoal Agents: An OverviewAnti-Infective Agents in Medicinal Chemistry, 8
G. Stork, D. Niu, A. Fujimoto, E. Koft, J. Balkovec, J. Tata, G. Dake (2001)
The first stereoselective total synthesis of quinine.Journal of the American Chemical Society, 123 14
I. Valéa, H. Tinto, M. Traoré-Coulibaly, L. Toe, N. Lindegårdh, J. Tarning, J. Geertruyden, U. d’Alessandro, G. Davies, S. Ward (2014)
Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso.The Journal of antimicrobial chemotherapy, 69 9
Rimeh Daghrir, P. Drogui (2013)
Tetracycline antibiotics in the environment: a reviewEnvironmental Chemistry Letters, 11
M. Pinazo, J. Muñoz, E. Posada, P. López-Chejade, M. Gállego, E. Ayala, E. Cacho, D. Soy, J. Gascón (2010)
Tolerance of Benznidazole in Treatment of Chagas' Disease in AdultsAntimicrobial Agents and Chemotherapy, 54
A. Moon, H. Biggs, M. Rubach, J. Crump, V. Maro, W. Saganda, Elizabeth Reddy (2014)
Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of MalariaPLoS ONE, 9
Advait Nagle, Agnes Biggart, Celine Be, H. Srinivas, Andreas Hein, Diana Caridha, R. Sciotti, Brandon Pybus, Mara Kreishman-Deitrick, B. Bursulaya, Yin Lai, Mu-Yun Gao, Fang-Ping Liang, Casey Mathison, Xiaodong Liu, V. Yeh, Jeffrey Smith, Isabelle Lerario, Yongping Xie, Donatella Chianelli, Michael Gibney, Ashley Berman, Yen-Liang Chen, Jan Jiricek, Lauren Davis, Xianzhong Liu, Jaime Ballard, Shilpi Khare, F. Eggimann, Alexandre Luneau, T. Groessl, Michael Shapiro, Wendy Richmond, Kevin Johnson, P. Rudewicz, Srinivasa Rao, Christopher Thompson, T. Tuntland, Glen Spraggon, R. Glynne, Frantisek Supek, Christian Wiesmann, V. Molteni (2020)
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of LeishmaniasesJournal of Medicinal Chemistry, 63
S. Croft, S. Duparc, S. Arbe-Barnes, J. Craft, C. Shin, L. Fleckenstein, I. Borghini-Fuhrer, H. Rim (2012)
Review of pyronaridine anti-malarial properties and product characteristicsMalaria Journal, 11
(2019)
New benznidazole regimens
K. Collins, T. Rückle, S. Elliott, L. Marquart, E. Ballard, S. Chalon, P. Griffin, J. Möhrle, J. McCarthy (2019)
DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 63
Weltgesundheitsorganisation (2005)
World malaria report
R. Chilengi, R. Juma, Ahmed Abdallah, M. Bashraheil, H. Lodenyo, P. Nyakundi, Evelyn Anabwani, Amina Salim, G. Mwambingu, Ednah Wenwa, Julie Jemutai, Chemtai Kipkeu, G. Oyoo, S. Muchohi, G. Kokwaro, T. Niehues, T. Lang, A. Nzila (2011)
A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteersMalaria Journal, 10
(2021)
Miltefosine/paromomycin phase iii trial for treatment of primary visceral leishmaniasis (VL) patients in Eastern Africa
E. Torres-Guerrero, M. Quintanilla-Cedillo, J. Ruiz-Esmenjaud, R. Arenas (2017)
Leishmaniasis: a reviewF1000Research, 6
Vishal Goyal, S. Burza, K. Pandey, S. Singh, Ravindra Singh, Nathalie Strub-Wourgaft, V. Das, C. Bern, A. Hightower, S. Rijal, T. Sunyoto, F. Alves, N. Lima, P. Das, J. Alvar (2019)
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, IndiaPLoS Neglected Tropical Diseases, 13
Kevin Kobylinski, M. Sylla, P. Chapman, M. Sarr, B. Foy (2011)
Ivermectin mass drug administration to humans disrupts malaria parasite transmission in Senegalese villages.The American journal of tropical medicine and hygiene, 85 1
M. Nunes, Wistremundo Dones, C. Morillo, J. Encina, A. Ribeiro (2013)
Chagas disease: an overview of clinical and epidemiological aspects.Journal of the American College of Cardiology, 62 9
S. Sundar, P. Sinha, S. Dixon, Renata Buckley, A. Miller, Khadeeja Mohamed, Mahir Al-Banna (2011)
Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India.The American journal of tropical medicine and hygiene, 84 6
M. Thaker, Peter Spanogiannopoulos, Gerard Wright (2010)
The tetracycline resistomeCellular and Molecular Life Sciences, 67
J. Gutman, S. Kovacs, G. Dorsey, A. Stergachis, F. Kuile (2017)
Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysisThe Lancet. Infectious Diseases, 17
(2020)
Innovative single-dose oral sleeping sickness treatment to be co-developed by Sanofi and DNDi partnership
Tanya Paquet, C. Manach, Diego Cabrera, Yassir Younis, P. Henrich, Tara Abraham, Marcus Lee, Rajshekhar Basak, S. Ghidelli-Disse, M. Lafuente-Monasterio, M. Bantscheff, A. Ruecker, A. Blagborough, S. Zakutansky, A. Zeeman, K. White, David Shackleford, Janne Mannila, Julia Morizzi, C. Scheurer, Iñigo Angulo-Barturen, M. Martínez, S. Ferrer, L. Sanz, F. Gamo, J. Reader, Mariette Botha, K. Dechering, R. Sauerwein, Anchalee Tungtaeng, P. Vanachayangkul, Chek Lim, J. Burrows, M. Witty, K. Marsh, C. Bodenreider, R. Rochford, S. Solapure, M. Jiménez-Díaz, S. Wittlin, S. Charman, C. Donini, B. Campo, L. Birkholtz, Kirsten Hanson, G. Drewes, C. Kocken, M. Delves, D. Leroy, D. Fidock, D. Waterson, L. Street, K. Chibale (2017)
Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinaseScience Translational Medicine, 9
Yuxiang Dong, Xiaofang Wang, Sriraghavan Kamaraj, V. Bulbule, F. Chiu, J. Chollet, M. Dhanasekaran, Christopher Hein, Petros Papastogiannidis, Julia Morizzi, David Shackleford, Helena Barker, E. Ryan, C. Scheurer, Yuanqing Tang, Qingjie Zhao, Lin Zhou, K. White, H. Urwyler, W. Charman, H. Matile, S. Wittlin, S. Charman, J. Vennerstrom (2017)
Structure-Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439).Journal of medicinal chemistry, 60 7
E. Zijlstra, W. Sande, O. Welsh, E. Mahgoub, M. Goodfellow, A. Fahal (2016)
Mycetoma: a unique neglected tropical disease.The Lancet. Infectious diseases, 16 1
A. Eziefula, T. Bousema, S. Yeung, M. Kamya, A. Owaraganise, Grace Gabagaya, J. Bradley, Lynn Grignard, K. Lanke, H. Wanzira, A. Mpimbaza, S. Nsobya, N. White, E. Webb, S. Staedke, C. Drakeley (2014)
Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.The Lancet. Infectious diseases, 14 2
Erica Dahl, Jennifer Shock, Bhaskar Shenai, J. Gut, J. Derisi, P. Rosenthal (2006)
Tetracyclines Specifically Target the Apicoplast of the Malaria Parasite Plasmodium falciparumAntimicrobial Agents and Chemotherapy, 50
M. Sands, M. Kron, R. Brown (1985)
Pentamidine: a review.Reviews of infectious diseases, 7 5
F. Torrico, J. Gascón, L. Ortiz, C. Alonso-Vega, M. Pinazo, A. Schijman, I. Almeida, F. Alves, Nathalie Strub-Wourgaft, I. Ribeiro (2018)
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.The Lancet. Infectious diseases, 18 4
(2021)
Medicines for Malaria Venture, MMV-supported projects
B. Coulibaly, M. Pritsch, Mamadou Bountogo, P. Meissner, E. Nébié, C. Klose, M. Kieser, N. Berens-Riha, A. Wieser, S. Sirima, J. Breitkreutz, R. Schirmer, A. Sié, F. Mockenhaupt, C. Drakeley, T. Bousema, O. Müller (2015)
Efficacy and safety of triple combination therapy with artesunate-amodiaquine-methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso.The Journal of infectious diseases, 211 5
H. Peixoto, M. Brito, G. Romero, W. Monteiro, M. Lacerda, M. Oliveira (2015)
G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost studyMalaria Journal, 14
Crystal Patil, SS Katare, M. Baig, S. Doifode (2014)
Fixed Dose Combination of Arterolane and Piperaquine: A Newer Prospect in Antimalarial TherapyAnnals of Medical and Health Sciences Research, 4
F. Akinsolu, Priscilla Nemieboka, D. Njuguna, Makafui Ahadji, D. Dezső, O. Varga (2019)
Emerging Resistance of Neglected Tropical Diseases: A Scoping Review of the LiteratureInternational Journal of Environmental Research and Public Health, 16
M. Chughlay, Myriam Gaaloul, C. Donini, B. Campo, Pieter-Jan Berghmans, A. Lucardie, M. Marx, Mohammed Cherkaoui-Rbati, G. Langdon, Iñigo Angulo-Barturen, Sara Viera, A. Rosanas-Urgell, J. Geertruyden, S. Chalon (2021)
Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection StudyThe American Journal of Tropical Medicine and Hygiene, 104
(2021)
Oral miltefosine plus topical imiquimod to treat cutaneous leishmaniasis
N. Carvalho, Fernanda Prates, Rafael Silva, Mayra Dourado, C. Amorim, P. Machado, F. Pacheco, T. Corte, Pablo Machado, D. Santos, E. Carvalho (2017)
In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous LeishmaniasisJournal of Immunology Research, 2017
R. Gürtler, M. Cardinal (2015)
Reservoir host competence and the role of domestic and commensal hosts in the transmission of Trypanosoma cruzi.Acta tropica, 151
R. Desowitz (1999)
Milestones and Millstones in the History of Malaria
S. Staedke, M. Kamya, G. Dorsey, Anne Gasasira, G. Ndeezi, E. Charlebois, P. Rosenthal (2001)
Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trialThe Lancet, 358
Asher Mullard (2018)
2017 FDA drug approvalsNature Reviews Drug Discovery, 17
D. Kioy, J. Jannin, N. Mattock (2004)
Focus: Human African trypanosomiasisNature Reviews Microbiology, 2
CDC -Malaria -Diagnosis & Treatment (United States) -Treatment
F. Leite, A. Fonseca, Renata Nunes, Moacyr Junior, Fernando Varotti, A. Taranto (2013)
Malária: Dos velhos fármacos aos novos alvos molecularesBBR - Biochemistry and biotechnology reports, 2
Paul O’Neill, B. Park, Alison Shone, James Maggs, P. Roberts, Paul Stocks, Giancarlo Biagini, Patrick Bray, Peter Gibbons, N. Berry, Peter Winstanley, Amira Mukhtar, R. Bonar-Law, S. Hindley, Ramesh Bambal, Charles Davis, M. Bates, Timothy Hart, Stephanie Gresham, Ron Lawrence, Richard Brigandi, Federico Gomez-delas-Heras, Domingo Gargallo, Stephen Ward (2009)
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.Journal of medicinal chemistry, 52 5
G. Romero, D. Costa, C. Costa, R. Almeida, E. Melo, Sílvio Carvalho, A. Rabello, Andrea Carvalho, A. Sousa, R. Leite, Simone Lima, Thaís Amaral, F. Alves, Joelle Rode (2017)
Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trialPLoS Neglected Tropical Diseases, 11
S. Wyllie, S. Brand, Michael Thomas, M. Rycker, C. Chung, Imanol Peña, Ryan Bingham, Juan Bueren-Calabuig, J. Cantizani, D. Cebrián, P. Craggs, L. Ferguson, P. Goswami, J. Hobrath, Jonathan Howe, Laura Jeacock, E. Ko, J. Korczynska, Lorna MacLean, Sujatha Manthri, M. Martínez, Lydia Mata-Cantero, S. Moniz, Andrea Nühs, Maria Osuna-Cabello, É. Pinto, Jennifer Riley, Sharon Robinson, P. Rowland, Frederick Simeons, Y. Shishikura, D. Spinks, L. Stojanovski, John Thomas, S. Thompson, Elisabet Gaza, Richard Wall, F. Zuccotto, D. Horn, M. Ferguson, A. Fairlamb, J. Fiandor, Julio Martin, David Gray, T. Miles, I. Gilbert, K. Read, Maria Marco, P. Wyatt (2019)
Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibitionProceedings of the National Academy of Sciences of the United States of America, 116
M. Rottmann, B. Jonat, Christin Gumpp, Satish Dhingra, Marla Giddins, Xiaoyan Yin, L. Badolo, B. Greco, D. Fidock, C. Oeuvray, T. Spangenberg (2020)
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation InhibitorAntimicrobial Agents and Chemotherapy, 64
Grennady Wirjanata, Boni Sebayang, F. Chalfein, Prayoga, Irene Handayuni, Rintis Noviyanti, E. Kenangalem, J. Poespoprodjo, S. Burgess, D. Peyton, Richard Price, Richard Price, J. Marfurt (2015)
Contrasting Ex Vivo Efficacies of “Reversed Chloroquine” Compounds in Chloroquine-Resistant Plasmodium falciparum and P. vivax IsolatesAntimicrobial Agents and Chemotherapy, 59
Hla Myint, E. Ashley, N. Day, N. Day, F. Nosten, F. Nosten, N. White, Nicholas White (2007)
Efficacy and safety of dihydroartemisinin-piperaquine.Transactions of the Royal Society of Tropical Medicine and Hygiene, 101 9
S. Fu, S. Xiao (1991)
Pyronaridine: A new antimalarial drug.Parasitology today, 7 11
M. Booth (2018)
Climate Change and the Neglected Tropical DiseasesAdvances in Parasitology, 100
A. Aguiar, E. Rocha, N. Souza, T. França, A. Krettli (2012)
New approaches in antimalarial drug discovery and development: a review.Memorias do Instituto Oswaldo Cruz, 107 7
J. Dingemanse, A. Krause (2017)
Impact of pharmacokinetic‐pharmacodynamic modelling in early clinical drug developmentEuropean Journal of Pharmaceutical Sciences, 109
(2021)
Why are some tropical diseases called ‘neglected’
J. Massarelli (1984)
Harrison's Principles of Internal MedicineJAMA, 251
E. Ashley, A. Phyo (2018)
Drugs in Development for MalariaDrugs, 78
N. Valecha, S. Krudsood, N. Tangpukdee, S. Mohanty, S. Sharma, P. Tyagi, A. Anvikar, R. Mohanty, B. Rao, A. Jha, B. Shahi, J. Singh, A. Roy, P. Kaur, M. Kothari, S. Mehta, A. Gautam, J. Paliwal, S. Arora, N. Saha (2012)
Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 55 5
S. Wyllie, A. Roberts, S. Norval, Stephen Patterson, B. Foth, M. Berriman, K. Read, A. Fairlamb (2016)
Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in LeishmaniaPLoS Pathogens, 12
S. Shiomi, Remi Misaka, Mayu Kaneko, H. Ishikawa (2019)
Enantioselective total synthesis of the unnatural enantiomer of quinine† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9sc03879eChemical Science, 10
Dana Klug, M. Gelb, M. Pollastri (2016)
Repurposing strategies for tropical disease drug discovery.Bioorganic & medicinal chemistry letters, 26 11
Yifei Dai, Weiwei Zhou, Jing Meng, Xin-liang Du, Yun-Peng Sui, Li Dai, Pengqian Wang, H. Huo, Feng Sui (2017)
The pharmacological activities and mechanisms of artemisinin and its derivatives: a systematic reviewMedicinal Chemistry Research, 26
(2021)
Seasonal malaria chemoprevention with sulfadoxinepyrimethamine plus amodiaquine in children: A field guide
R. Tuteja (2007)
Malaria − an overviewThe FEBS Journal, 274
J. Karbwang, K. Na-Bangchang (1997)
PHARMACOKINETICS AND DISPOSITION
Vishal Goyal, R. Mahajan, K. Pandey, S. Singh, Ravindra Singh, Nathalie Strub-Wourgaft, F. Alves, Vidya Das, R. Topno, B. Sharma, M. Balasegaram, C. Bern, A. Hightower, S. Rijal, S. Ellis, T. Sunyoto, S. Burza, N. Lima, P. Das, J. Alvar (2018)
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, IndiaPLoS Neglected Tropical Diseases, 12
M. Wahajuddin, S. Singh, Isha Taneja, K. Raju, J. Gayen, H. Siddiqui, Shio Singh (2015)
Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97–78 in rat plasma using the HPLC–ESI-MS/MS method: application to drug interaction studyMalaria Journal, 14
(2021)
WHO, Cases of sleeping sickness drop to lowest level in 75 years
S. Bouwman, Rella Zoleko-Manego, K. Renner, E. Schmitt, G. Mombo-Ngoma, M. Grobusch (2020)
The early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound.Travel medicine and infectious disease
R. Howes, F. Piel, Anand Patil, O. Nyangiri, P. Gething, Mewahyu Dewi, Mariana Hogg, K. Battle, Carmencita Padilla, Carmencita Padilla, J. Baird, Simon Hay (2012)
G6PD Deficiency Prevalence and Estimates of Affected Populations in Malaria Endemic Countries: A Geostatistical Model-Based MapPLoS Medicine, 9
M. Rycker, B. Baragaña, S. Duce, I. Gilbert (2018)
Challenges and recent progress in drug discovery for tropical diseasesNature, 559
S. Pushpakom, Francesco Iorio, P. Eyers, K. Escott, Shirley Hopper, A. Wells, A. Doig, Tim Guilliams, Joanna Latimer, Christina McNamee, A. Norris, P. Sanseau, D. Cavalla, M. Pirmohamed (2018)
Drug repurposing: progress, challenges and recommendationsNature Reviews Drug Discovery, 18
(2018)
Kuziena, J.‐P
E. Deeks (2019)
Fexinidazole: First Global ApprovalDrugs, 79
D. Mondal, C. Bern, D. Ghosh, M. Rashid, R. Molina, R. Chowdhury, R. Nath, P. Ghosh, L. Chapman, A. Alim, G. Bilbe, J. Alvar (2018)
Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand FliesClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 69
(2011)
Evaluation of fosmidomycin and azithromycin when administered concurrently to adult subjects with acute uncomplicated Plasmodium salciparum malaria
(2021)
Report of the fifth consultative meeting on leishmania/ HIV coinfection
A. Llanos-Cuentas, M. Casapia, R. Chuquiyauri, J. Hinojosa, Nicola Kerr, M. Rosario, S. Toovey, R. Arch, M. Phillips, Felix Rozenberg, J. Bath, Caroline Ng, A. Cowell, E. Winzeler, D. Fidock, M. Baker, J. Möhrle, R. Huijsduijnen, N. Gobeau, Nada Araeipour, Nicole Andenmatten, T. Rückle, S. Duparc (2018)
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a studyThe Lancet. Infectious Diseases, 18
E. Diro, S. Blesson, T. Edwards, K. Ritmeijer, Helina Fikre, Henok Admassu, Aderajew Kibret, S. Ellis, Clélia Bardonneau, E. Zijlstra, Peninah Soipei, Brian Mutinda, R. Omollo, Robert Kimutai, Gabriel Omwalo, M. Wasunna, Fentahun Tadesse, F. Alves, Nathalie Strub-Wourgaft, A. Hailu, N. Alexander, J. Alvar (2019)
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in EthiopiaPLoS Neglected Tropical Diseases, 13
R. Jacobs, B. Nare, S. Wring, M. Orr, Daitao Chen, J. Sligar, M. Jenks, R. Noe, Tana Bowling, Luke Mercer, C. Rewerts, E. Gaukel, Jennifer Owens, R. Parham, R. Randolph, B. Beaudet, C. Bacchi, N. Yarlett, J. Plattner, Y. Freund, C. Ding, T. Akama, Y.‐K. Zhang, R. Brun, M. Kaiser, Ivan Scandale, R. Don (2011)
SCYX-7158, an Orally-Active Benzoxaborole for the Treatment of Stage 2 Human African TrypanosomiasisPLoS Neglected Tropical Diseases, 5
H. Bryson, K. Goa (2012)
HalofantrineDrugs, 43
B. Foy, H. Alout, Jonathan Seaman, Sangeeta Rao, T. Magalhaes, M. Wade, S. Parikh, D. Soma, A. Sagna, F. Fournet, Hannah Slater, R. Bougma, F. Drabo, A. Diabaté, Gafar Coulidiaty, N. Rouamba, R. Dabiré (2019)
Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trialLancet (London, England), 393
S. Sundar, P. Sinha, Madhukar Rai, Deepak Verma, F. Modabber (2011)
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trialThe Lancet, 377
D. Legros, G. Ollivier, M. Gastellu-Etchegorry, C. Paquet, C. Burri, J. Jannin, P. Büscher (2002)
Treatment of human African trypanosomiasis--present situation and needs for research and development.The Lancet. Infectious diseases, 2 7
C. Boss, H. Aissaoui, Nathalie Amaral, A. Bauer, Stephanie Bazire, C. Binkert, R. Brun, Cédric Bürki, Claire-Lise Ciana, Olivier Corminboeuf, S. Delahaye, Claire Dollinger, Christoph Fischli, W. Fischli, Alexandre Flock, Marie-Céline Frantz, Malory Girault, C. Grisostomi, Astrid Friedli, Bibia Heidmann, Claire Hinder, Gael Jacob, Amelie Le Bihan, S. Malrieu, Saskia Mamzed, Aurélien Merot, Solange Meyer, Sabrina Peixoto, Nolwenn Petit, Romain Siegrist, J. Trollux, T. Weller, S. Wittlin (2016)
Discovery and Characterization of ACT‐451840: an Antimalarial Drug with a Novel Mechanism of ActionChemMedChem, 11
Om Patel, Richard Beteck, L. Legoabe (2020)
Antimalarial application of quinones: A recent update.European journal of medicinal chemistry, 210
S. Bruderer, N. Hurst, R. Kanter, Tommaso Miraval, T. Pfeifer, Y. Donazzolo, J. Dingemanse (2014)
First-in-Humans Study of the Safety, Tolerability, and Pharmacokinetics of ACT-451840, a New Chemical Entity with Antimalarial ActivityAntimicrobial Agents and Chemotherapy, 59
Kelly Smith, J. Leyden (2005)
Safety of doxycycline and minocycline: a systematic review.Clinical therapeutics, 27 9
B. Nare, S. Wring, C. Bacchi, B. Beaudet, Tana Bowling, R. Brun, Daitao Chen, C. Ding, Y. Freund, E. Gaukel, A. Hussain, K. Jarnagin, M. Jenks, M. Kaiser, Luke Mercer, Elena Mejia, Andy Noe, M. Orr, R. Parham, J. Plattner, R. Randolph, D. Rattendi, C. Rewerts, J. Sligar, N. Yarlett, R. Don, R. Jacobs (2010)
Discovery of Novel Orally Bioavailable Oxaborole 6-Carboxamides That Demonstrate Cure in a Murine Model of Late-Stage Central Nervous System African TrypanosomiasisAntimicrobial Agents and Chemotherapy, 54
Yizhe Chen, Fangyi Zhu, Jared Hammill, Gloria Holbrook, Lei Yang, B. Freeman, K. White, David Shackleford, Kathleen O’Loughlin, Liang Tang, S. Charman, J. Mirsalis, R. Guy (2020)
Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolonesMalaria Journal, 20
G. Priotto, S. Kasparian, W. Mutombo, D. Ngouama, S. Ghorashian, U. Arnold, S. Ghabri, E. Baudin, V. Buard, S. Kazadi-Kyanza, M. Ilunga, W. Mutangala, G. Pohlig, C. Schmid, U. Karunakara, E. Torreele, V. Kande (2009)
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialThe Lancet, 374
John Okombo, K. Chibale (2018)
Recent updates in the discovery and development of novel antimalarial drug candidates.MedChemComm, 9 3
V. Levin, M. Prados, W. Yung, M. Gleason, S. Ictech, M. Malec (1992)
Treatment of recurrent gliomas with eflornithine.Journal of the National Cancer Institute, 84 18
Aditya Gaur, James McCarthy, J. Panetta, Ronald Dallas, J. Woodford, L. Tang, Amber Smith, Tracy Stewart, Kristen Branum, Burgess Freeman, Nehali Patel, E. John, S. Chalon, S. Ost, Ryan Heine, Julie Richardson, R. Christensen, Patricia Flynn, Y. Gessel, Branko Mitasev, J. Möhrle, F. Gusovsky, Lidiya Bebrevska, R Guy (2020)
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.The Lancet. Infectious diseases
(2020)
African Trypanosomiasis-resources for health professionals
S. Ramanathan-Girish, P. Catz, Moire Creek, Benjamin Wu, David Thomas, D. Krogstad, D. De, J. Mirsalis, C. Green (2004)
Pharmacokinetics of the Antimalarial Drug, AQ-13, in Rats and Cynomolgus MacaquesInternational Journal of Toxicology, 23
W. Stolk, Margarete Kulik, E. Rutte, J. Jacobson, J. Richardus, S. Vlas, T. Houweling (2016)
Between-Country Inequalities in the Neglected Tropical Disease Burden in 1990 and 2010, with Projections for 2020PLoS Neglected Tropical Diseases, 10
M. Roberts (2003)
Tetracycline therapy: update.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 36 4
(2021)
GHO | By category | Estimated deaths—Estimates by region
J. Urbina, G. Payares, L. Contreras, Andreina Liendo, C. Sanoja, J. Molina, M. Piras, R. Piras, N. Perez, P. Wincker, D. Loebenberg (1998)
Antiproliferative Effects and Mechanism of Action of SCH 56592 against Trypanosoma (Schizotrypanum)cruzi: In Vitro and In Vivo StudiesAntimicrobial Agents and Chemotherapy, 42
Omm, Pnuma (2003)
Climate change and human health: risks and responses. Summary
J. Dziekan, Han Yu, Dan Chen, Lingyun Dai, Grennady Wirjanata, Andreas Larsson, N. Prabhu, R. Sobota, Zbynek Bozdech, P. Nordlund (2019)
Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assayScience Translational Medicine, 11
E. Tse, Marat Korsik, M. Todd (2019)
The past, present and future of anti-malarial medicinesMalaria Journal, 18
E. Beek (2020)
Drugs for Neglected Diseases initiative; Best Science for the Most Neglected
V. Carrara, J. Zwang, E. Ashley, R. Price, K. Stepniewska, M. Barends, A. Brockman, Tim Anderson, R. McGready, L. Phaiphun, S. Proux, M. Vugt, R. Hutagalung, K. Lwin., A. Phyo, P. Preechapornkul, M. Imwong, S. Pukrittayakamee, P. Singhasivanon, N. White, F. Nosten (2009)
Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous DeploymentPLoS ONE, 4
K. Thriemer, A. Bobogare, B. Ley, Clarice Gudo, M. Alam, N. Anstey, E. Ashley, J. Baird, C. Gryseels, E. Jambert, M. Lacerda, F. Laihad, J. Marfurt, A. Pasaribu, J. Poespoprodjo, I. Sutanto, W. Taylor, C. Boogaard, K. Battle, L. Dysoley, P. Ghimire, Bill Hawley, J. Hwang, W. Khan, R. Mudin, M. Sumiwi, Rukhsana Ahmed, M. Aktaruzzaman, K. Awasthi, A. Bardají, D. Bell, Leonard Boaz, F. Burdam, D. Chandramohan, Q. Cheng, Keobouphaphone Chindawongsa, J. Culpepper, Santasabuj Das, R. Deray, M. Desai, G. Domingo, Wang Duoquan, S. Duparc, Rustini Floranita, E. Gerth-Guyette, R. Howes, C. Hugo, G. Jagoe, E. Sariwati, S. Jhora, Wu Jinwei, H. Karunajeewa, E. Kenangalem, B. Lal, Chandra Landuwulang, Emmanuel Perru, Sang-Eun Lee, L. Makita, J. McCarthy, A. Mekuria, N. Mishra, Esau Naket, S. Nambanya, Johnny Nausien, Thang Duc, Thuan Thi, Rinitis Noviyanti, Daniel Pfeffer, G. Qi, Annisa Rahmalia, S. Rogerson, Iriani Samad, J. Sattabongkot, A. Satyagraha, D. Shanks, S. Sharma, C. Sibley, Ali Sungkar, D. Syafruddin, A. Talukdar, J. Tarning, F. Kuile, S. Thapa, Minerva Theodora, T. Huy, Edward Waramin, G. Waramori, Adugna Woyessa, C. Wongsrichanalai, Nguyen Xa, J. Yeom, Lukas Hermawan, A. Devine, Spike Nowak, Indra Jaya, S. Supargiyono, K. Grietens, R. Price (2018)
Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working GroupMalaria Journal, 17
N. Aronson, B. Herwaldt, M. Libman, R. Pearson, R. López-Vélez, P. Weina, E. Carvalho, M. Ephros, S. Jerônimo, A. Magill (2017)
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)*The American Journal of Tropical Medicine and Hygiene, 96
L. Serghides, Samir Patel, Kodjo Ayi, Ziyue Lu, D. Gowda, W. Liles, K. Kain (2009)
Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria.The Journal of infectious diseases, 199 10
R. Rahman, Vishal Goyal, R. Haque, K. Jamil, A. Faiz, Rasheda Samad, S. Ellis, M. Balasegaram, M. Boer, S. Rijal, Nathalie Strub-Wourgaft, F. Alves, J. Alvar, B. Sharma (2017)
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in BangladeshPLoS Neglected Tropical Diseases, 11
J. Altcheh, G. Moscatelli, S. Moroni, F. Garcia-Bournissen, H. Freilij (2011)
Adverse Events After the Use of Benznidazole in Infants and Children With Chagas DiseasePediatrics, 127
C. Polyak, K. Yuhas, B. Singa, M. Khaemba, J. Walson, B. Richardson, G. John-Stewart (2016)
Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority TrialPLoS Medicine, 13
S. Ōmura, A. Crump (2017)
Ivermectin and malaria controlMalaria Journal, 16
G. Camarda, P. Jirawatcharadech, R. Priestley, A. Saif, Sandra March, Michael Wong, S. Leung, Alex Miller, D. Baker, P. Alano, M. Paine, S. Bhatia, P. O’Neill, S. Ward, G. Biagini (2019)
Antimalarial activity of primaquine operates via a two-step biochemical relayNature Communications, 10
Jelena Lewis, T. Gregorian, I. Portillo, J. Goad (2019)
Drug interactions with antimalarial medications in older travelers: a clinical guide.Journal of travel medicine
L. Sánchez, J. Ramírez (2012)
Congenital and oral transmission of American trypanosomiasis: an overview of physiopathogenic aspectsParasitology, 140
T. Dorlo, A. Kip, B. Younis, S. Ellis, F. Alves, J. Beijnen, S. Njenga, G. Kirigi, A. Hailu, J. Olobo, A. Musa, M. Balasegaram, M. Wasunna, M. Karlsson, E. Khalil (2017)
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic studyJournal of Antimicrobial Chemotherapy, 72
(2006)
Role of US military research programs in the development of US Food and Drug Administration--approved antimalarial drugs.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 43 1
Y. Jackson, E. Alirol, L. Gétaz, H. Wolff, C. Combescure, F. Chappuis (2010)
Tolerance and safety of nifurtimox in patients with chronic chagas disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 51 10
K. Jain, N. Jain (2013)
Novel therapeutic strategies for treatment of visceral leishmaniasis.Drug discovery today, 18 23-24
J. Karbwang, K. Bangchang (1994)
Clinical Pharmacokinetics of HalofantrineClinical Pharmacokinetics, 27
(2021)
Thermotherapy + a short course of miltefosine for the treatment of uncomplicated cutaneous leishmaniasis in the new world
Richard Wall, E. Rico, Iva Lukac, F. Zuccotto, S. Elg, I. Gilbert, Y. Freund, M. Alley, Mark Field, S. Wyllie, D. Horn (2018)
Clinical and veterinary trypanocidal benzoxaboroles target CPSF3Proceedings of the National Academy of Sciences, 115
(2014)
Safety of 8-Aminoquinoline Antimalarial Medicines, World Health Organization
P. Verma, A. Jha (2018)
Mycetoma: reviewing a neglected diseaseClinical and Experimental Dermatology, 44
M. Simões-Silva, J. Araújo, R. Peres, P. Silva, M. Batista, L. Azevedo, M. Bastos, M. Bahia, N. Boechat, M. Soeiro (2019)
Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruziParasitology, 146
J. Urbina, G. Payares, C. Sanoja, R. Lira, A. Romanha (2003)
In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease.International journal of antimicrobial agents, 21 1
N. White, S. Pukrittayakamee, A. Phyo, F. Nosten, Atthanee Jeeyapant, J. Jain, Ruobing Li, T. Diagana, Joel Leong (2014)
Spiroindolone KAE609 for falciparum and vivax malaria.The New England journal of medicine, 371 5
Marit Moen, K. McKeage, G. Plosker, M Siddiqui (2012)
ImatinibDrugs, 67
A. Klainer (1987)
Clindamycin.The Medical clinics of North America, 71 6
J. Aagaard-Hansen, Nohelly Nombela, J. Alvar (2010)
Population movement: a key factor in the epidemiology of neglected tropical diseasesTropical Medicine & International Health, 15
M. Willcox, G. Bodeker, P. Rasoanaivo, J. Addae-Kyereme (2004)
Traditional Medicinal Plants and Malaria
M. Crockett, K. Kain (2007)
Tafenoquine: a promising new antimalarial agentExpert Opinion on Investigational Drugs, 16
Esperança Sevene, C. Banda, M. Mukaka, Sónia Maculuve, Salésio Macuácua, Anifa Valá, M. Piqueras, L. Kalilani‐Phiri, J. Mallewa, D. Terlouw, S. Khoo, D. Lalloo, V. Mwapasa (2019)
Efficacy and safety of dihydroartemisinin–piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trialMalaria Journal, 18
D. Steverding (2010)
The development of drugs for treatment of sleeping sickness: a historical reviewParasites & Vectors, 3
J. Vennerstrom, S. Arbe-Barnes, R. Brun, S. Charman, F. Chiu, J. Chollet, Yuxiang Dong, A. Dorn, D. Hunziker, H. Matile, K. McIntosh, M. Padmanilayam, J. Tomas, C. Scheurer, B. Scorneaux, Yuanqing Tang, H. Urwyler, S. Wittlin, W. Charman (2004)
Identification of an antimalarial synthetic trioxolane drug development candidateNature, 430
J. Fernández, J. Chicharro, J. Bueno, Milagros Lorenzo (2016)
Isoxazole mediated synthesis of 4-(1H)pyridones: improved preparation of antimalarial candidate GSK932121.Chemical communications, 52 66
Michael Thomas, M. Rycker, M. Ajakane, S. Albrecht, A. Álvarez-Pedraglio, Markus Boesche, S. Brand, Lorna Campbell, Juan Cantizani-Perez, Laura Cleghorn, R. Copley, Sabrinia Crouch, A. Daugan, G. Drewes, S. Ferrer, S. Ghidelli-Disse, Silvia González, S. Gresham, A. Hill, S. Hindley, R. Lowe, Claire Mackenzie, Lorna MacLean, Sujatha Manthri, Franck Martin, Juan Miguel-Siles, Van-Loc Nguyen, S. Norval, Maria Osuna-Cabello, Andrew Woodland, Stephen Patterson, Imanol Peña, Maria Quesada-Campos, Iain Reid, Charlotte Revill, Jennifer Riley, J. Ruiz-Gomez, Y. Shishikura, Frederick Simeons, Alasdair Smith, V. Smith, D. Spinks, L. Stojanovski, John Thomas, S. Thompson, Tim Underwood, David Gray, J. Fiandor, I. Gilbert, P. Wyatt, K. Read, T. Miles (2018)
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral LeishmaniasisJournal of Medicinal Chemistry, 62
O. Koita, Lansana Sangaré, Haiyan Miller, A. Sissako, M. Coulibaly, Trevor Thompson, S. Fongoro, Y. Diarra, Mamadou Ba, A. Maiga, B. Diallo, D. Mushatt, Frances Mather, J. Shaffer, Asif Anwar, D. Krogstad (2017)
AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trialThe Lancet. Infectious Diseases, 17
Guangyu Lu, Guangyu Lu, M. Nagbanshi, N. Goldau, M. Jorge, P. Meissner, Albrecht Jahn, F. Mockenhaupt, Olaf Müller (2018)
Efficacy and safety of methylene blue in the treatment of malaria: a systematic reviewBMC Medicine, 16
G. Silva, Mauro Mediano, A. Hasslocher-Moreno, M. Holanda, A. Sousa, L. Sangenis, P. Brasil, R. Mejía, C. Fux, Juan-Carlos Cubides, R. Saraiva, L. Brum-Soares (2017)
Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' diseaseJournal of Antimicrobial Chemotherapy, 72
F. Alves, G. Bilbe, S. Blesson, Vishal Goyal, S. Monnerat, C. Mowbray, Gina Ouattara, B. Pécoul, S. Rijal, Joelle Rode, Alexandra Solomos, Nathalie Strub-Wourgaft, M. Wasunna, S. Wells, E. Zijlstra, B. Arana, J. Alvar (2018)
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and PerspectivesClinical Microbiology Reviews, 31
M. Kasten (1999)
Clindamycin, metronidazole, and chloramphenicol.Mayo Clinic proceedings, 74 8
M. Jorge, Lucienne Ouermi, P. Meissner, Guillaume Compaoré, B. Coulibaly, E. Nébié, J. Krisam, C. Klose, M. Kieser, A. Jahn, G. Lu, Umberto Alessandro, A. Sié, F. Mockenhaupt, O. Müller (2019)
Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trialPLoS ONE, 14
James Smith, E. Taylor (2016)
What Is Next for NTDs in the Era of the Sustainable Development Goals?PLoS Neglected Tropical Diseases, 10
L. Cui, S. Mharakurwa, D. Ndiaye, P. Rathod, P. Rosenthal (2015)
Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkThe American Journal of Tropical Medicine and Hygiene, 93
A. Musa, E. Khalil, A. Hailu, J. Olobo, M. Balasegaram, R. Omollo, T. Edwards, J. Rashid, J. Mbui, Brima Musa, A. Abuzaid, O. Ahmed, A. Fadlalla, A. El-Hassan, Marius Mueller, Geoffrey Mucee, S. Njoroge, V. Manduku, G. Mutuma, Lilian Apadet, H. Lodenyo, Dedan Mutea, G. Kirigi, Sisay Yifru, G. Mengistu, Zewdu Hurissa, Workagegnehu Hailu, Teklu Weldegebreal, Hailemariam Tafes, Y. Mekonnen, E. Makonnen, S. Ndegwa, Patrick Sagaki, Robert Kimutai, Josephine Kesusu, Rhoda Owiti, S. Ellis, M. Wasunna (2012)
Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled TrialPLoS Neglected Tropical Diseases, 6
(2021)
WHO policy recommendation: Seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa
Els Torreele, Bernadette Trunz, David Tweats, Marcel Kaiser, Reto Brun, Guy Mazué, Michael Bray, Bernard Pécoul (2010)
Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping SicknessPLoS Neglected Tropical Diseases, 4
(2018)
Leishmaniasis-status of endemicity of leishmaniais
S. Pukrittayakamee, Arun Chantra, S. Vanijanonta, R. Clemens, S. Looareesuwan, N. White (2000)
Therapeutic Responses to Quinine and Clindamycin in Multidrug-Resistant Falciparum MalariaAntimicrobial Agents and Chemotherapy, 44
Katy Olafson, Megan Ketchum, J. Rimer, P. Vekilov (2015)
Mechanisms of hematin crystallization and inhibition by the antimalarial drug chloroquineProceedings of the National Academy of Sciences, 112
C. Alving (1921)
Walter Reed Army Institute of Research (WRAIR): Fifty Years of Achievements That Impact Science and SocietyMilitary Medicine, 186
Kristina Kesely, A. Pantaleo, F. Turrini, P. Olupot‐Olupot, P. Low (2016)
Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates ParasitemiaPLoS ONE, 11
M. Missinou, S. Borrmann, A. Schindler, S. Issifou, A. Adegnika, P. Matsiegui, R. Binder, B. Lell, J. Wiesner, T. Baranek, H. Jomaa, P. Kremsner (2002)
Fosmidomycin for malariaThe Lancet, 360
N. Wiedemar, Dennis Hauser, P. Mäser (2019)
100 Years of SuraminAntimicrobial Agents and Chemotherapy, 64
Thakur Cp, T. Kanyok, A. Pandey, G. Sinha, A. Zaniewski, Heather Houlihan, P. Olliaro (2000)
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.Transactions of the Royal Society of Tropical Medicine and Hygiene, 94 4
Liliana López, I. Velez, C. Asela, C. Cruz, F. Alves, S. Robledo, B. Arana (2018)
A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in ColombiaPLoS Neglected Tropical Diseases, 12
Ellen Gadelha, S. Talhari, Jorge Guerra, Leandro Neves, C. Talhari, B. Gontijo, Roberto Júnior, A. Talhari (2015)
Efficacy and safety of a single dose pentamidine (7mg/kg) for patients with cutaneous leishmaniasis caused by L. guyanensis: a pilot study*Anais Brasileiros de Dermatologia, 90
James Rosling, Melanie Ridgway, R. Summers, K. Kirk, Adele Lehane (2018)
Biochemical characterization and chemical inhibition of PfATP4-associated Na+-ATPase activity in Plasmodium falciparum membranesThe Journal of Biological Chemistry, 293
F. Smithuis, M. Kyaw, O. Phe, T. Win, Pyay Aung, Aung Oo, Arkar Naing, Mya Nyo, Naing Myint, M. Imwong, E. Ashley, Sue Lee, N. White (2010)
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trialThe Lancet. Infectious Diseases, 10
Taisa Berbert, T. Mello, Priscila Nassif, Camila Mota, A. Silveira, G. Duarte, I. Demarchi, S. Aristides, M. Lonardoni, Jorge Teixeira, T. Silveira (2018)
Pentavalent Antimonials Combined with Other Therapeutic Alternatives for the Treatment of Cutaneous and Mucocutaneous Leishmaniasis: A Systematic ReviewDermatology Research and Practice, 2018
R. Lawrence, Katherine Dennis, P. O’Neill, D. Hahn, M. Roeder, C. Struppe (2008)
Development of a Scalable Synthetic Route to GSK369796 (N-tert-Butyl Isoquine), a Novel 4-Aminoquinoline Antimalarial DrugOrganic Process Research & Development, 12
S. Bhatt, D. Weiss, E. Cameron, D. Bisanzio, B. Mappin, U. Dalrymple, K. Battle, C. Moyes, Andrew Henry, P. Eckhoff, E. Wenger, O. Briët, O. Briët, M. Penny, M. Penny, T. Smith, T. Smith, A. Bennett, J. Yukich, T. Eisele, J. Griffin, C. Fergus, Michael Lynch, F. Lindgren, Justin Cohen, C. Murray, Dave Smith, S. Hay, S. Hay, S. Hay, R. Cibulskis, P. Gething (2015)
The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015Nature, 526
Y. Taslimi, F. Zahedifard, S. Rafati (2016)
Leishmaniasis and various immunotherapeutic approachesParasitology, 145
Issaka Fofa, I. Sagara, A. Béavogui, I. Zongo, I. Soulama, I. Borghini-Fuhrer, Bakary Fofana, Aliou Traoré, N. Diallo, Hamadoun Diakité, A. Togo, S. Koumare, M. Keita, D. Camara, A. Somé, A. Coulibaly, O. Traore, Souleymane Dama, S. Goita, Moussa Djimdé, Amadou Bamadio, Niawanlou Dara, Hamma Maiga, Bouran Sidibé, Francois Dao, M. Coulibaly, M. Alhousseini, H. Niangaly, B. Sangare, M. Diarra, Samba Coumare, M. Kabore, S. Ouattara, Aissata Barry, D. Kargougou, A. Diarra, N. Henry, Harouna Sorè, Edith Bougouma, Ismaila Thera, Y. Compaoré, C. Sutherland, M. Sylla, Frederic Nikiema, M. Diallo, A. Dicko, S. Picot, S. Borrmann, S. Duparc, Robert Miller, O. Doumbo, Jangsik Shin, J. Gil, A. Björkman, J. Ouédraogo, S. Sirima, A. Djimde (2018)
Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trialLancet (London, England), 391
R. Omollo, N. Alexander, T. Edwards, E. Khalil, B. Younis, A. Abuzaid, M. Wasunna, Njenga Njoroge, D. Kinoti, G. Kirigi, T. Dorlo, S. Ellis, M. Balasegaram, A. Musa (2011)
Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trialTrials, 12
Neglected tropical diseases are a diverse group of communicable diseases that are endemic in low‐ or low‐to‐middle‐income countries located in tropical and subtropical zones. The number and availability of drugs for treating these diseases are low, the administration route is inconvenient in some cases, and most of them have safety, efficacy, or adverse/toxic reaction issues. The need for developing new drugs to deal with these issues is clear, but one of the most drastic consequences of this negligence is the lack of interest in the research and development of new therapeutic options among major pharmaceutical companies. Positive changes have been achieved over the last few years, although the overall situation remains alarming. After more than one decade since the original work reviewing antiprotozoal agents came to light, now it is time to question ourselves: How has the scenario for the treatment of protozoal diseases such as malaria, leishmaniasis, human African trypanosomiasis, and American trypanosomiasis changed? This review covers the last decade in terms of the drugs currently available for the treatment of these diseases as well as the clinical candidates being currently investigated.
Archiv Der Pharmazie – Wiley
Published: Feb 1, 2022
Keywords: Chagas disease; leishmaniasis; malaria; medicinal chemistry; neglected diseases; parasitic diseases; sleeping sickness
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.